Jiangsu Kingsley Pharmaceutical Co., Ltd.

Primary Objective: To evaluate the bioequivalence and efficacy consistency of the test formulation and the reference formulation, fosphenytoin sodium injection (10 mL: 500 mg (calculated as C15H11N2NaO2), manufactured by Jiangsu Jinshili Pharmaceutical Co., Ltd.), after intravenous administration of the test formulation fosphenytoin sodium injection (500 mg/10 mL (calculated as C15H11N2NaO2), licensee: Parke Davis Div Warner Lambert Co., trade name: Cerebyx®), and the reference formulation phenytoin sodium injection (250 mg/5 mL, licensee: Hikma Pharmaceuticals USA Inc.), in healthy trial participants under fasting conditions, using pharmacokinetic parameters as the primary endpoint.